Please refer attachment

Revenue declinedNet loss reportedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹31.00

prior close

₹29.60

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-0.8% vs market

Commodity Chemicals peers, median of 51sector+0.5%-0.3% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.3 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2+0.9-0.8+0.5-0.3

Next day

+2.9+0.8+2.1-0.1+3.0

-1.9+0.7-2.7-0.4-1.5

+0.0+1.3-1.3-0.8+0.8

-2.3+0.5-2.8-1.9-0.3

+2.6+0.4+2.2-1.4+4.0

+4.4-1.5+5.8-1.8+6.2

15d

-6.8-2.4-4.4-3.7-3.2

-5.5-4.4-1.1-6.7+1.3

-3.0-7.2+4.2-10.0+7.0

-11.6-5.0-6.6-11.8+0.2

UpDownMarket · Nifty Microcap 250Sector · Commodity Chemicals peers, median of 51Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emmessar Biotech & Nutrition Ltd submitted its unaudited financial results for Q2 FY26 and the half year ended September 30, 2025, which were reviewed by V. Nagarajan & Co. and approved by the Board on November 12, 2025. Total income for Q2 FY26 came in at Rs 125.74 lakhs, sharply lower than Rs 261.96 lakhs in Q2 FY25 (a roughly 50% drop year-on-year). For the half year, the company swung from a small profit of Rs 27.85 lakhs in H1 FY25 to a loss before tax of about Rs (64.21) lakhs in H1 FY26. The auditor's limited review report is clean, with no qualifications or emphasis-of-matter issues raised.

Likely market impact

This is a negative result for shareholders — revenue has halved compared to the same quarter last year and the company has slipped from profit into loss. Expect weak sentiment on the stock unless management provides a clear turnaround plan.